Sam Brusco, Associate Editor12.10.21
Hologic and subsidiary Biotheranostics released new data showing Breast Cancer Index (BCI) both predicts preferential recurrence-prevention benefit from extended endocrine therapy (EET) and overall risk/benefit and likelihood of improved health from EET in certain hormone receptor positive (HR+) patients.
New data also confirmed two biomarkers used in BCI are interconnected drivers to assess recurrences in HR+ breast cancer.
“Extended endocrine therapy often comes with tolerability challenges and even significant adverse events,” study author Marc Buyse, ScD, Associate Professor of Biostatistics at Hasselt University in Belgium told the press. “We found the data to have considerable implications for patient compliance and joint decision-making with their healthcare providers, as patients have a more comprehensive picture of the net benefit of staying on EET so they can better assess the challenges that can come with treatment.”
Research shows EET might reduce long-term risk of recurrence in HR+ breast cancer, but treatment is often accompanied by bone toxicity, endometrial cancer, embolisms, heart disease, and more.1-3 Hologic’s study examined the relationship of proliferation and endocrine response to support how the BCI assay works. Data confirmed two biomarkers contributing to BCI’s risk assessment drove tumor biology, validating BCI’s role for personalized extended endocrine decisions.
“These data analyzing H/I and MGI genes solidify our understanding of the relationship between these two critical components of BCI,” said study author Reshma Mahtani, DO, Professor of Medicine at the University of Miami, Sylvester Comprehensive Cancer Center. “The insights confirm H/I and MGI are interdependent contributors of risk and benefit thus both necessary elements working in combination to determine risk of recurrences in HR+ breast cancer, further ensuring providers are equipped to make informed prognoses in routine care with BCI.”
References
1 Davies C et al., Lancet. 2013; 381(9869):805-16.
2 Goss PE et al., N Engl J Med. 2016 Jun 5 (Online).
3 Mamounas EP et al. San Antonio Breast Cancer Symposium, 2016.
New data also confirmed two biomarkers used in BCI are interconnected drivers to assess recurrences in HR+ breast cancer.
“Extended endocrine therapy often comes with tolerability challenges and even significant adverse events,” study author Marc Buyse, ScD, Associate Professor of Biostatistics at Hasselt University in Belgium told the press. “We found the data to have considerable implications for patient compliance and joint decision-making with their healthcare providers, as patients have a more comprehensive picture of the net benefit of staying on EET so they can better assess the challenges that can come with treatment.”
Research shows EET might reduce long-term risk of recurrence in HR+ breast cancer, but treatment is often accompanied by bone toxicity, endometrial cancer, embolisms, heart disease, and more.1-3 Hologic’s study examined the relationship of proliferation and endocrine response to support how the BCI assay works. Data confirmed two biomarkers contributing to BCI’s risk assessment drove tumor biology, validating BCI’s role for personalized extended endocrine decisions.
“These data analyzing H/I and MGI genes solidify our understanding of the relationship between these two critical components of BCI,” said study author Reshma Mahtani, DO, Professor of Medicine at the University of Miami, Sylvester Comprehensive Cancer Center. “The insights confirm H/I and MGI are interdependent contributors of risk and benefit thus both necessary elements working in combination to determine risk of recurrences in HR+ breast cancer, further ensuring providers are equipped to make informed prognoses in routine care with BCI.”
References
1 Davies C et al., Lancet. 2013; 381(9869):805-16.
2 Goss PE et al., N Engl J Med. 2016 Jun 5 (Online).
3 Mamounas EP et al. San Antonio Breast Cancer Symposium, 2016.